FY2026 EPS Estimate for Bausch Health Cos Raised by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Equities research analysts at Zacks Research boosted their FY2026 EPS estimates for Bausch Health Cos in a research note issued on Wednesday, August 19th. Zacks Research analyst Team now expects that the company will post earnings per share of $4.24 for the year, up from their prior estimate of $3.93. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.24 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q4 2026 earnings at $1.16 EPS.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. The company had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion.

A number of other analysts have also commented on BHC. Jefferies Financial Group raised Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Royal Bank Of Canada cut their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday, April 27th. Finally, Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $6.88 on Thursday. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -2.32 and a beta of 0.38. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.44. Bausch Health Cos has a fifty-two week low of $4.33 and a fifty-two week high of $8.00. The firm’s 50-day simple moving average is $5.30 and its 200 day simple moving average is $5.45.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos in the 1st quarter worth approximately $68,000. Jones Financial Companies Lllp lifted its stake in Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after purchasing an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Bausch Health Cos by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after purchasing an additional 467,270 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Bausch Health Cos by 3.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock valued at $2,102,000 after purchasing an additional 9,834 shares during the period. Finally, Geode Capital Management LLC increased its position in Bausch Health Cos by 11.2% in the second quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after buying an additional 84,892 shares during the last quarter. 78.65% of the stock is owned by institutional investors.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.